Gastroparesis is a syndrome of delayed gastric emptying caused by factors other than mechanical obstructions in the stomach.
The 2014 outbreak in West Africa is the largest epidemic to date. Preventive strategies and supportive therapy are the only options, since no vaccine or effective antiviral treatment is yet available.
Pharmacists can oversee postprocedural treatment administered to prevent atrioesophageal fistula, a serious complication.
Liver cirrhosis is the end result of several mechanisms of liver inflammation caused by chronic liver disease, genetic disease, or autoimmune inflammation.
Recent studies have shown that drug absorption may be impaired in CD patients who require oral medications for comorbid conditions.
The most important risk factor for acquiring this virulent infection is antibiotic administration.
Patients with diabetes often experience foot complications, such as ulcers, infections, and even amputations.1
Adverse drug events are an important factor influencing health outcomes of individuals treated with psychotropic medications.
Many nonpsychiatric medications have the potential to cause neuropsychiatric events ranging from anxiety to psychosis.
Treatment options include lifestyle modifications, psychotherapy, and pharmacotherapy.
Psychopathy is a serious personality disorder that can have significant negative effects both on individuals and on society.
It is often the behavioral symptoms associated with disease progression that lead to hospitalization.
Depending upon the severity of symptoms, patients may be treated in the inpatient or outpatient setting.
This agent may be an alternative for patients with pain severe enough to require around-the-clock, long-term opioid therapy when other options are inadequate.
Through screening for early detection of cognitive impairment and dementia, patients have a better chance of managing their diabetes at home with provider assistance.
The proposed rule will replace existing regulations and provide detailed, current information for patients and their providers.
This article reviews five new drugs (umeclidinium and vilanterol, vortioxetine, dapagliflozin, luliconazole, sofosbuvir) that were approved by the FDA in the past year.
Five new molecular entities (riociguat, ibrutinib, obinutuzumab, coagulation factor XIII A-subunit [recombinant], collagenase clostridium histolyticum) that were recently approved by the FDA are discussed.
New guidelines recommend chemoprevention (tamoxifen or raloxifene) for high-risk patients.
Women are underrepresented and gender-specific analysis is uncommon in most clinical trials.
For more articles, please check our archives.